Form 4: Amgen EVP David Reese Reports Stock Disposition

Amgen Inc. Executive Vice President and Chief Technology Officer David M. Reese reported the disposition of 1,433 shares of common stock to cover tax obligations.

Summary

• David M. Reese, EVP & Chief Technology Officer of Amgen Inc., disposed of a total of 1,433 shares of common stock.
• The transactions occurred on May 2, 2026, at a price of $329.82 per share.
• The shares were withheld by the company to satisfy tax withholding obligations related to the vesting of equity awards.
• Following these transactions, the reporting person maintains a direct beneficial ownership of 40,354 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a routine administrative action related to tax obligations rather than a discretionary sale of stock.

Positives

• The transaction reflects the vesting of equity-based compensation, aligning executive interests with long-term shareholder value.

Negatives

• The transaction represents a reduction in the executive's direct equity holdings in the company.

Risks

• None identified; this is a routine administrative transaction related to tax withholding.

Future Outlook

Not applicable; this is a retrospective disclosure of an insider transaction.

Industry Context

StockSavvy.ai notes that tax-related share withholding is a standard practice for corporate executives in the biotechnology sector to manage tax liabilities upon the vesting of restricted stock units.

Comparison to Industry Standards

• The transaction follows standard corporate governance practices for executive compensation and tax compliance observed at large-cap pharmaceutical companies like Pfizer, Gilead, and AbbVie.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a mandatory tax withholding event.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Amgen, AMGN, Insider Trading, Form 4, Equity Compensation, Biotechnology